[{"orgOrder":0,"company":"HealthTech BioActives","sponsor":"HealthTech BioActives","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Other Small Molecule","year":"2021","type":"Acquisition","leadProduct":"VAR-101","moa":"PKC?","graph1":"Oncology","graph2":"Preclinical","graph3":"HealthTech BioActives","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Topical","sponsorNew":"HealthTech BioActives \/ HealthTech BioActives","highestDevelopmentStatusID":"4","companyTruncated":"HealthTech BioActives \/ HealthTech BioActives"}]

Find Clinical Drug Pipeline Developments & Deals by HealthTech BioActives

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : VAR-101

                          Therapeutic Area : Oncology

                          Study Phase : Preclinical

                          Recipient : Varian Biopharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          Details : Varian Bio’s lead drug candidate, VAR-101, is being developed in a topical formulation for the treatment of basal cell carcinoma. VAR-102, an oral formulation, is being developed for the treatment of a wide variety of solid tumors.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          March 31, 2021

                          Lead Product(s) : VAR-101

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Varian Biopharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          HealthTech BioActives